| HOME >> BIOLOGY >> TECHNOLOGY |
SAN DIEGO, Aug. 1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the Bank of America 2008 Specialty Pharmaceuticals Conference on Friday, August 8, 2008 at 8:45 a.m. EDT (5:45 a.m. PDT). The conference is being held at the Southampton Inn in Long Island, New York.
Steve Worland, Ph.D., President and Chief Executive Officer of Anadys Pharmaceuticals, Inc., will present an overview of Anadys and its two development-stage product candidates, ANA598 and ANA773.
The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through August 22, 2008.
About Anadys
Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing ANA598, a non-nucleoside polymerase inhibitor, and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical in
nature constitute "forward-looking statements." Such statements include,
but are not limited to, references to Anadys' strategy, development
programs, and ability to develo
'/>"/>
| SOURCE Anadys Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |